About Us

Dr. Ira W. Lieberman
Chairman of the Board

Dr. Ira W. Lieberman has been a member of our board of directors since December 2004. Since October 2004, Dr. Lieberman has served as President and Chief Executive Officer of LIPAM International, Inc., an advisory and investment firm, which performs advisory and consulting work for the World Bank Institute, client governments, and private sector clients. From July 2003 to October 2004, Dr. Lieberman served as a Senior Economic Advisor to George Soros for the Open Society Institute, a grant making foundation. From February 1993 to July 2004, Dr. Lieberman served in several positions for the World Bank Institute. Dr. Lieberman received an MBA from Columbia University and a Ph.D. from Oxford University.

Ms. Julia R. Brown has been a member of our board of directors since April 2012.  Ms. Julia R. Brown has held a variety of executive positions over her 40 year career in the pharmaceutical industry.  From 2000-2003, Ms. Brown was Executive Vice President of Amylin Pharmaceuticals, Inc., responsible for commercial operations.  She served as Advisor to the CEO until 2008.  Prior to joining Amylin, Ms. Brown was Executive Vice President of Dura Pharmaceuticals, Inc.  Ms. Brown spent over 25 years with Eli Lilly and Company in progressively more senior roles including Vice President of IVAC Corporation and General Manager of its Vital Signs Division and Vice President of Worldwide Marketing for Hybritech.

Ms. Brown is currently a member of the board of directors of Targacept, Inc. and serves as chair of its compensation committee. She has previously served on the board of directors of several other development stage pharmaceutical or biopharmaceutical companies.  She is a member of the National Association of Corporate Directors, Women Corporate Directors and is a member of the board of Corporate Directors Forum—all organizations which are dedicated to high standards of professionalism in corporate governance. Ms. Brown chairs the board of trustees of the UC San Diego Foundation.  She is a member of the board of CONNECT, an organization that fosters innovation, entrepreneurship and the formation of new companies in southern California.  Ms. Brown is a graduate of Louisiana Tech University where she studied microbiology and biochemistry.

Dr. Errol De Souza joined the Biodel management team as President and CEO as well as the Board of Directors in March of 2010.  Dr. De Souza has nearly two decades of experience in the field of drug discovery and development.  Since January 2009, Dr. De Souza has been a pharmaceutical and biotechnology consultant.  From April 2003 to January 2009, Dr. De Souza was President and Chief Executive Officer of Archemix Corporation, a biopharmaceutical company focused on aptamer therapeutics. From September 2002 to March 2003, he was President and Chief Executive Officer and a Director of Synaptic Pharmaceuticals.  As a result of a merger effective March 2003, Synaptic Pharmaceuticals became a wholly-owned subsidiary of H. Lundbeck A/S, an international pharmaceutical company.  Prior to that, Dr. De Souza held senior management positions with Aventis, and its predecessor company Hoechst Marion Roussel Pharmaceuticals, and was co-founder of Neurocrine Biosciences, Inc.  He is currently a Director of several biopharmaceutical companies including Bionomics Limited and Targacept, Inc.  Dr. De Souza received his B.A. (Honors) in physiology and his Ph.D. in neuroendocrinology from the University of Toronto and he received his postdoctoral fellowship in neuroscience from The Johns Hopkins University School of Medicine.

Barry Ginsberg, M.D., Ph.D., has been a member of our board of directors since June 2008. Dr. Ginsberg currently serves as Chief Executive Officer of Diabetes Technology Consultants and holds over 25 years of experience in diabetes. Prior to Diabetes Technology Consultants, Dr. Ginsberg served as Vice President of Worldwide Medical Affairs in the Diabetes HealthCare Division at Becton Dickinson during his 17 year tenure. Dr. Ginsberg currently serves as Chairman of the Scientific Advisory Boards at Agamatrix and Therafuse, and is a Scientific Advisory Board Member at Covidien, Metacure, Glucolight and Becton Dickinson Diabetes HealthCare. Dr. Ginsberg received both an M.D. and Ph.D. in Molecular Biology from Albert Einstein College of Medicine.

Dr. Daniel Lorber has been a member of our board of directors since December 2004 and since October 2004, a member of our scientific advisory board. Since 1981, Dr. Lorber has served as the medical director of the Diabetes Control Foundation, Diabetes Care and Information Center in Flushing, New York and since 1991, as the director of endocrinology at The New York Hospital Medical Center of Queens. Dr. Lorber is also an attending physician in endocrinology and general internal medicine at the New York Hospital Medical Center of Queens. Since 1994, Dr. Lorber has served as a clinical associate professor of medicine at Weill Medical College of Cornell University. Dr. Lorber also serves as a consultant in medical, dental and podiatric liability litigation and to the insurance industry on care standards for diabetes mellitus. Dr. Lorber is a member of the board of directors of the American Diabetes Association. Dr. Lorber received an M.D. from the Albert Einstein College of Medicine and completed a fellowship in endocrinology at the Vanderbilt University Medical Center.

Dr. Brian Pereira has been a member of our board of directors since November 2007. Dr. Pereira joined AMAG Pharmaceuticals as President in November 2005, and was appointed Chief Executive Officer in November 2006. Prior to joining the company, he was President and CEO of New England Health Care Foundation, a physician's group at Tufts-New England Medical Center from 2001 to 2005, and held various other positions at Tufts-New England Medical Center from 1993 to 2001. From 2002 to 2004, he served as President of the National Kidney Foundation, and served on the editorial board of twelve scientific journals. Dr. Pereira is a nationally-recognized expert on kidney disease and nephrology, and is the Editor of the widely read textbook "Chronic Kidney Disease, Dialysis and Transplantation" and has over 200 scientific papers to his credit. He is a Professor of Medicine at Tufts University School of Medicine and at the Sackler School of Biomedical Sciences of Tufts University. Dr. Pereira currently serves on the board of directors of the National Kidney Foundation and Biodel Inc. Dr. Pereira is a graduate of St. John's Medical College, Bangalore, India and has an MBA from the Kellogg Business School, Northwestern University.

Davey S. Scoon, C.P.A. has been a member of our board of director since April 2012.  Mr. Davey S. Scoon’s business career has included senior executive positions in Finance and Administration across a range of industries including asset management, insurance, retailing and consumer products.  His board leadership positions include board chair and audit chair positions in industries including mutual funds, health insurance and life sciences.

Mr. Scoon is currently the non-executive Chairman of Tufts Health Plan, Chair of the board of trustees for Allianz Global Investors and a board member and Audit Chair of AMAG Pharmaceuticals, Inc. and Orthofix International N.V. Previously he served as the Chairman of the audit committees of NitroMed, Inc. and CardioKine, Inc.  In addition to his board work, Mr. Scoon is an adjunct professor teaching accounting at the University of Wisconsin-Madison.

Mr. Scoon is an audit committee financial expert having been a Chief Financial Officer in the manufacturing, financial services and retailing industries.  He has an extensive background in risk management, has operated successfully in strictly regulated industries, has been involved in M&A activities throughout his career and has a thorough working knowledge of Sarbanes Oxley.

Mr. Scoon’s previous corporate experience includes Chief Administrative and Financial Officer of Tom’s of Maine, Inc., Chief Administrative and Financial Officer of Sunlife Financial U.S., Executive Vice President and Chief Operating Officer of Liberty Funds Group of Boston (formerly Colonial Management) and Certified Public Accountant with Price Waterhouse & Company.  Mr. Davey earned an MBA from Harvard Business School and a BBA in Business Administration from the University of Wisconsin.

Dr. Charles Sanders has been our Chairman Emeritus since April 2012. Previously he served as a member of our board of directors from August 2006 to April 2012, during which he served as chairman of the board from March 2010 to March 2011. Since 1995, Dr. Sanders has served on numerous boards and continues to chair the boards of Project Hope and the Foundation for the National Institutes of Health. From July 1989 to July 1994, Dr. Sanders served as Chief Executive Officer of Glaxo Inc., a pharmaceutical company, and from 1992 until his retirement in 1995, served as the Chairman of the Board of Glaxo Inc. Previously Dr. Sanders was general director of Massachusetts General Hospital and professor of medicine at Harvard Medical School. Dr. Sanders received an M.D. from Southwestern Medical College of the University of Texas. Dr. Sanders serves on the boards of directors of Icagen, Inc., a biopharmaceutical company, Vertex Pharmaceuticals Incorporated, a biotechnology company, Cephalon, Inc., a biopharmaceutical company, and BioCryst Pharmaceuticals, Inc., a biopharmaceutical company.